Heterogeneous Expression of Wnt/beta-catenin Target Genes Within Colorectal Cancer
Overview
Affiliations
Invasion of common colorectal adenocarcinomas is coupled with a transient loss of epithelial differentiation of tumor cells. Previously, we have shown that dedifferentiated tumor cells at the invasive front (IF) accumulate the transcriptional activator beta-catenin in the nucleus, in contrast to cells of the tumor center. To characterize the cells of these two morphogenic tumor areas, gene expression profiling was performed. Our study demonstrates that intratumorous heterogeneity in colorectal cancer correlates with differential expression of 510 genes between the central tumor region (TC) and the IF. Many genes differentially expressed at the IF are involved in cellular invasion processes like cell motility, cell adhesion and extracellular matrix interaction. This in vivo analysis shows overexpression of known Wnt/beta-catenin target genes either in the entire tumor tissue (compared to normal mucosa) or specifically at the IF. Thus, even though all tumor cells overexpress beta-catenin, the existence of at least 2 groups of Wnt/beta-catenin target genes selectively activated in different tumor regions is suggested. The concomitant high expression of inflammation- and tissue repair-related genes at the IF supports the hypothesis that an inflammation-activated microenvironment may trigger selective Wnt/beta-catenin target gene expression and contribute to the malignant progression of colorectal cancer.
Gonzalez-Moles M, Keim-Del Pino C, Ramos-Garcia P Int J Mol Sci. 2022; 23(21).
PMID: 36361889 PMC: 9658487. DOI: 10.3390/ijms232113099.
Jaitner S, Pretzsch E, Neumann J, Schaffauer A, Schiemann M, Angele M J Pathol Clin Res. 2022; 9(1):73-85.
PMID: 36349502 PMC: 9732686. DOI: 10.1002/cjp2.300.
Svec J, Stastna M, Janeckova L, Hrckulak D, Vojtechova M, Onhajzer J Cancers (Basel). 2022; 14(17).
PMID: 36077674 PMC: 9454662. DOI: 10.3390/cancers14174137.
Gonzalez-Moles M, Warnakulasuriya S, Lopez-Ansio M, Ramos-Garcia P Cancers (Basel). 2022; 14(15).
PMID: 35954497 PMC: 9367256. DOI: 10.3390/cancers14153834.
Groll T, Silva M, Sarker R, Tschurtschenthaler M, Schnalzger T, Mogler C Cancers (Basel). 2022; 14(9).
PMID: 35565377 PMC: 9105816. DOI: 10.3390/cancers14092248.